VPA can specifically inhibit HDAC1 and HDAC2, and previous studies have demonstrated that VPA treatment improves AKI(Ma et al., 2017), glomerular diseases (Inoue et al., 2019), and UUO(Van Beneden et al., 2013) in mice. Here, HDAC1 is linked to glomerular disorder.